Keywords: copd, drugs, predominate, astrazeneca, early-stage, pipeline, cytofab
COPD drugs predominate in AstraZeneca's early-stage pipeline; CytoFab nears Ph III
Article | 19 June 2006
At a recent business strategy meeting in London, UK, Anglo-Swedish drug major AstraZeneca disclosed details of its early-stage pipeline, revealing ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
